@misojin0713
Windtree Therapeutics (WINT) announced in July that it would establish a strategic reserve of BNB. However, due to weak fundamentals and a persistently low stock price, it ultimately received a delisting notice from Nasdaq on August 19th. Following the announcement, WINT's stock price plummeted, plummeting 77.21% in a single day to just $0.13, a 91.7% drop from its initial price of $1.58 following the announcement. For a small, clinical-stage biopharmaceutical company facing mounting quarterly losses and yet to achieve commercialization, delisting virtually means complete market marginalization.
0 reply
0 recast
0 reaction